Arisgen is a drug delivery company with a proprietary formulation technology that enables delivery of therapeutic peptides via oral or buccal/sub-lingual routes. Arisgen’s technology has the potential to transform the injectable peptide market offering oral alternatives for these medications. Arisgen aims to be a world leader in the development of orally available peptide drugs through development of its own products and partnerships that allow the application of the technology to proprietary peptide therapeutics.
Arisgen is currently developing a portfolio of novel products focused on the treatment of metabolic diseases and oncology. The lead programme is a novel fast acting oral form of a GLP-1 agonist for the treatment of diabetes which we expect to enter clinical development in 2015.
At Arisgen we are dedicated to building an exception team and developing the next generation drug delivery system for peptide drugs.